Summary:
Adoptive immunotherapy using natural killer (NK) cells may prove useful, especially in situations where infusion of T cells is impractical such as in recipients of haploidentical stem cell transplantation (HSCT) from haploidentical donors. NK cells may induce potent antileukemic and possibly antirejection activity and may even mitigate graft versus host disease (GvHD). Whether such effects are clinically important and whether they are mediated mainly or exclusively by KIR-HLA class I interactions remains to be determined. Recent advances in graft engineering provide for methods to isolate large numbers of purified NK cells. Several groups have shown that clinical grade NK cells up to a dose of 10 7 /kg may be collected and purified for the purpose of infusion to patients. Early results, in a limited number of patients, show that these cell doses may be administered without adverse events and without inducing GvHD. Whether such infusions will be useful in preventing graft rejection, or exerting graft versus leukemia effects and hastening immune recovery requires further study. 
Background

NK cells
Natural killer (NK) cells, described originally because of their ability to kill tumor and virally infected cells without previous stimulation, do not express clonally rearranged receptors to detect antigens. [1] [2] [3] They reside mainly in marrow, spleen, and peripheral blood where they comprise approximately 10% of peripheral blood lymphocytes. 4, 5 Cell surface receptors that inhibit and/or activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), lectins, and natural cytotoxicity receptors (NCRs). [6] [7] [8] [9] NK cells recognize MHC class I molecules via receptors, many of which exert negative, that is, inhibitory effects on the NK cell. NK inhibitory signals are mediated by KIRs and by C-type lectin receptor CD94:NKG2A heterodimer, which interact with MHC-I molecules on the target cells. Lack of engagement results in target cell lysis. These systems form the basis of the 'missing self' hypothesis and exemplify the mechanisms of the immune system to counteract MHC downregulation induced by tumors and viral infection to escape T-cell recognition. 10 All mature NK cells express at least one receptor specific for self MHC. KIRs are members of the immunoglobulin superfamily expressed on the surface of NK cells and a subset of T cells. They are encoded by highly polymorphic genes located on chromosome 19q13.4 in a region known as the leukocyte receptor cluster (LRC). The predominant ligand for inhibitory KIRs is HLA-C but HLA-B and HLA-A are also involved. Despite the complexity of HLA class I molecules acting as targets of NK cell receptors, the most prevalent and dominant pattern of alloreactivity is mediated by two public epitopes of HLA-C, which are determined by a simple asparagine/lysine dimorphism at position 80. Up to 13 KIR genes are expressed, and a number of KIR haplotypes have been determined that are primarily characterized by variation in the number of activating KIR genes. Approximately 50% of the population have a single activating receptor (KIR2DS4), whereas the rest carry genes for between 3 and 5, including the genes KIR2DS1 or KIR2DS2.
While inhibitory KIRs deactivate NK cells, activatory receptors (eg NCRs) are responsible for NK cell activation. The NK repertoire is incompletely understood. The lack of genes for certain families of activating receptors may play a role in HSCT, and also in NK-cell type large granular lymphocyte leukemia or autoimmune diseases. NCRs are specific for NK cells, while other epitopes such as CD56 are also found on T-cell subsets. The CD56 þ /CD3À cell population is, however, a reasonable approximation of the NK cell population. NK cells respond to cytokines, the killing activity can be enhanced by culture in IL-2, and some studies suggest that adoptive transfer of NK cell subsets in an activated state (ie after stimulation with IL-2, IL-12, IL-15, or combinations thereof) may be needed for optimal efficacy. NK cells can therefore be seen as a surveillance population of the early innate immune response, responding to danger signals via NCRs, and being inhibited upon engagement of inhibitory receptors with self-MHC, thus watching for attempt at escape via MHC downregulation.
Transplantation from mismatched (haploidentical) family donors
Haploidentical stem cell transplantation (HSCT) from mismatched family donors is a treatment option for patients lacking an HLA-identical sibling or a matched unrelated donor. As the MHC is inherited on chromosome 6, most patients lacking an HLA-identical sibling will have a haploidentical donor, that is, a sibling or parents or other relative sharing at least one of the two HLA haplotypes. Haploidentical HSCT remains difficult until today, even though progress has been made with the use of large doses of highly purified stem cells. Mostly, graft versus host disease (GvHD) is not a major problem due to extensive Tcell depletion but rejection remains frequent and immune reconstitution is slow with a high incidence of severe infectious complications. [14] [15] [16] [17] [18] [19] [20] Antileukemia activity of these transplants is limited. Lymphocyte and especially CD4 counts remain suppressed for a long time after a haploidentical HSCT, the first lymphoid population to recover are the NK cells. 21, 22 Such patients are candidates for adoptive immunotherapy to enhance immune reconstitution and graft versus leukemia effects.
NK-cell alloreactivity
NK-cell alloreactivity could be broadly defined as any NKcell effect against cells based on some form of allorecognition. Based on the HLA class I typing of recipient and donor, NK-cell alloreactivity, that is, a lack of inhibition of donor NK cells and hence killing activity can be expected, when the respective KIRs are not expressed on donor cells. More information on the presence of KIR epitopes can be gained by either measuring KIR expression by immunophenotyping, by genotyping KIR sequences, or by direct functional assay of cytotoxicity. Since KIR and HLA chromosomal regions segregate independently, studies drawing conclusions about the effect of donor KIR pattern on transplant outcome based on ligand presence alone, that is, predicting the effect of KIR genotype based solely on HLA genotype has been challenged.
NK cells may exert alloreactivity either in the graft versus host or the host versus graft direction. NK-cell alloreactivity in host versus graft direction was first described -albeit not understood -as the phenomenon of 'hybrid resistance' in a mouse transplantation model in the 1960s. In the clinical setting of HSCT after myeloablative conditioning, it rarely has any measurable effects due to the intense nature of the conditioning regimen effectively ablating host NK cells before transplantation. In transplant regimens applying less-intense conditioning regimens, the contribution of NK-cell alloreactivity is unclear, as these settings are also associated with higher numbers of recipient T cells being present after conditioning and potentially being responsible for rejection. NK-cell alloreactivity in the graft versus host direction is of specific interest as NK cells may mediate graft versus leukemia and antirejection activity. There is evidence in animal studies of a multitude of potentially beneficial effects (summarized in Table 1 ) including NK vs leukemia activity, reducing relapse risks, NK vs residual host T-cell activity, reducing graft rejection risks and NK vs host dendritic cell activity potentially associated with reduced GvHD risks, as antigen presentation by host dendritic cells has been implied as the initiating event in GvHD. [23] [24] [25] [26] Furthermore, in animal studies, alloreactive NK cells have been successfully used in conjunction with lower than usual doses of irradiation to condition recipients of HLA-disparate grafts, thus using cellular intervention as part of the pretransplant conditioning regimen. The restriction of NK-cell alloreactivity to hematopoetic cells may explain its lack of association with GvHD.
In human studies, a positive outcome of KIR/HLA disparity has been demonstrated in the setting of haploidentical HSCT. Lower than expected rates of leukemia relapse in patients with AML, a lower rate of graft rejection and a paradoxical reduction in GvHD were noted when the haploidentical graft possessed inhibitory KIRs for which the recipient had no ligand. 23 Alloreactive NK clones that killed recipient leukemic blasts in vitro were isolated from the recipient following the transplant. While patients with lymphoid neoplasms such as ALL also seem to benefit from a reduction of the incidence of graft rejection and GvHD, relapse rate was not influenced by the presence of a KIR/ HLA-mismatch, suggesting that the antileukemic activity is specific for patients suffering from myeloid leukemia.
To learn more about whether NK-cell alloreactivity exerting graft versus leukemia effects could be demonstrated in other transplant settings, studies were undertaken in unrelated donor transplantation where large cohorts of donor recipient pairs with HLA-testing data were available. In a study involving 175 heterogeneous unrelated donor transplant recipients, no effects on graft failure, GvHD, or relapse rates were observed associated with KIR incompatibility. 27 In a similar study with 130 patients, all receiving ATG as part of the conditioning regimen, thus undergoing Table 1 Potential benefit and harm of adoptive immunotherapy using NK cells in HSCT recipients (for most of these, there is no evidence or only limited evidence available in the human situation) at least partial in vivo T-cell depletion, patients with NK-cell alloreactivity had a higher probability of overall survival and disease-free survival compared to those without NK-cell alloreactivity. Transplant-related mortality for the two groups was 6 and 40%, respectively. Relapse rates for patients receiving transplants from a donor with or without KIR ligand incompatibility were 6 and 21%, respectively. 28 The assessment of NK-cell alloreactivity in unrelated donor transplantation, obtained based on HLA typing data, remains therefore inconclusive. 29 Similarly in centers practicing T-cell depletion in HLA-identical sibling transplants, AML patients lacking KIR ligand for donor KIR had higher survival probabilities. 30 Some of the findings could be explained by effects of NK-cell alloreactivity becoming visible in the absence of T cells while being obfuscated by stronger T-cell-mediated effects in transplants without T-cell depletion. 31, 32 Other studies found even a deleterious effect of KIR mismatching. In HLA-identical sibling transplants for myeloid leukemia, patients carrying a lys80-type allele on both HLA-C loci and thus lacking the ligands for the inhibitory KIR2DL2/ 2DL3 had impaired survival but only if the donor carried the activatory KIR gene KIR2DS2 (seen in 10 vs 12 patients). 33 This may point to a more complex interaction between inhibitory and activating NK-cell receptors.
The huge difference observed in some studies between the susceptibility of AML cells vs ALL cells to NK-cell alloreactivity remains unexplained. Hypotheses include that adhesion molecules, such as LFA1 (CD11a), absent on ALL cells, may be necessary for NK-cell-mediated killing. More recent studies provide evidence of NK-cell alloreactivity in pediatric patients with ALL, once the KIR repertoire is measured rather than delineated from HLA typing. 34 
Adoptive immunotherapy/donor lymphocyte infusion
Adoptive immunotherapy using donor lymphocyte infusion (DLI) has become standard practice in patients relapsing after HSCT, since their description in patients with CML in 1990. 35 DLI may be administered in bulk doses or in graded incremental doses and lower doses may be beneficial because of less GvHD.
36,37 DLI appear to be highly effective in slowly progressing diseases such as CML and less so in diseases with rapid proliferation, possibly due to the fact that graft versus leukemia activity is a process that requires sufficient time to develop. DLI appear also to be less effective in lymphatic diseases such as ALL than in AML or CML, but this has been challenged by more favorable data in low-grade lymphomas and CLL. Remission induction and maintenance by DLI is considered to be a direct consequence of graft versus leukemia effects. The major risk of DLI is GvHD, which may be fatal in some patients. To minimize these risks, investigators have been using modified strategies such as partially T-cell-depleted DLI. 38 DLI have been rarely used in recipients of haploidentical HSCT, mainly because of GvHD risks. Some investigators have been using very small doses of T cells to stabilize the graft and to promote immune reconstitution. 39 DLI with highly selected NK cells in recipients of haploidentical HSCT provide a model to study effects of NK cells and to better describe NK cell alloreactivity.
NK cell DLI
Based on the above, several groups have investigated the preparation and infusion of purified, T-cell-depleted, donor NK lymphocytes (NK-cell DLI) with the aim to (a) consolidate engraftment and (b) to induce graft versus leukemia effects, in patients after HSCT from haploidentical or other donors, hypothesizing that purified NK lymphocytes would preferentially recognize hematopoetic host cells, and promote engraftment and graft versus leukemia effects without inducing GvHD. Available data on NK-cell harvesting and purification are summarized in Table 2 , data on clinical outcome in Table 3 . Most of these studies include small numbers of patients, and have been published as abstracts only.
NK-cell harvesting and purification
In the Basel pilot study of NK-cell purification and infusion in patients after haploidentical HSCT, mononuclear cells were collected from the donor by 10 l leukapheresis. a NK-cell enrichment (CD56 þ ). Products with higher than targeted T-cell or NK-cell doses were split with one unit being infused immediately and the other unit cryopreserved in DMSO. The overall processing time was 8-10 h. After processing, the purity of CD56 þ /CD3À cells was 97.3% (median; range 77.9-98.9) with a recovery of NK cells of 35.5% (13.1-75.0). The main loss of CD56 þ cells occurred during the first step. Overall, a T-cell depletion of 3.55 (2.9-4.5) log was achieved. The total T-cell count was reduced from 481 Â 10 7 (284-1539) to 0.134 Â 10 7 (0.05-0.518). Of six products collected and purified for five patients, four were split, to obtain 10 infusable products. Prior to splitting, CD56 þ /CD3À cells were 1.61 Â . Apheresis volume was therefore doubled in order to allow for a significant loss of NK cells during engineering.
In a study by Iyengar et al, 12 leukapheresis products were purified to obtain NK cells for clinical use, using the same two-step immunomagnetic method. The median percentage of CD56 þ /CD3À NK cells in the final products was 91%, and the median recovery was 48.7%. The median depletion for T cells was 5.3 log. Natural cytotoxicity of the purified cells was approximately fivefold higher as compared to the unpurified mononuclear cells, and was increased further by stimulation with IL-2. 41 In a similar study by Koehl et al, 10 unstimulated leukaphereses were performed and purified by a two-step CD3 depletion with a final CD56 enrichment procedure. The median CD56 þ /CD3À NK cell content was 95% after the final selection step with a median recovery of 37%. The two-step depletion procedure led to a median percentage of 0.04% CD3 þ cells associated with a median residual T-cell number of 280 Â 10 3 CD3 þ cells (range 45-1100 Â 10 3 CD3 þ ) in the final product. 43 Uharek reported on a yield of 42% with 74% purity and a 4 log T-cell depletion and a dose of 0.76 Â 10 7 /kg prior to activation with IL-2. This group infused NK cells that had been separated from the stem cell apheresis product on day þ 2 of haploidentical HSCT. 42 Lang et al presented data on purification of 1-h leukapheresis products of four healthy donors. The median purity of NK cells was 98.6%, the NK cell dose achieved was 160 Â 10 6 CD56 þ /CD3À cells. Recovery was 42% and the T-cell depletion was 4.56 log. The enriched NK cells demonstrated high cytotoxic activity against K562 target cells (which lack class I HLA expression) and fresh leukemic blasts with low HLA class I expression, further enhanced by IL-2 stimulation. Lysing of NK-insensitive leukemic cells with high HLA class I expression could also be demonstrated via ADCC. Alloreactive proliferation in mixed lymphocyte cultures and response to T-cell-specific mitogen stimulation was profoundly decreased confirming extensive T-cell depletion. 44 The data on NK-DLI, obtained from haploidentical donors having previously undergone stem cell donation, may differ from data obtained in healthy volunteer donors. This may explain why the extent of T-cell depletion and NK-cell recovery was somewhat lower in our pilot protocol compared to other published data. The processing of NK-DLI is time consuming, and requires specific knowledge and skills in graft engineering. Prerequisites to an adequate number of NK cells for NK-DLI are a high number of CD56 þ cells in the leukapheresis product, and efficiency of in vitro processing.
NK-cell infusion
Five recipients of haploidentical HSCT with AML 4 or CML 1 with evidence of mixed chimerism or impending relapse, children or young adults were selected for the Basel pilot protocol. 46 Donors were parents. NK-alloreactivity prediction based on HLA typing was present in 3/5 patients. Indications for NK-DLI were incomplete engraftment in three, and early relapse, and graft failure in one patient, respectively. NK-DLI were given as an outpatient procedure, either immediately after processing or as cryopreserved NK units, thawed at the bedside and infused rapidly. During infusion of fresh or thawed NK products, no immediate adverse reactions were observed. None of the five patients developed clinical signs of acute or chronic GvHD, there were no infectious complications, and no other late effects were observed. Four of the five patients remain alive and well, and in continuous remission 8-18 months after the first NK-DLI (median follow-up: 12 months). One patient had rapidly progressive AML after NK-DLI and did not receive a second dose. After NK-DLI, two patients had an increase in donor chimerism, to either complete or near complete chimerism but one of them had received an additional stem cell dose after NK-DLI, one patient has stabilized a previously dropping mixed chimerism, and one patient continues to drop donor chimerism.
Uharek et al described six recipients of haploidentical CD34 þ cell grafts receiving an add-back of 1 Â 10 7 IL-2-activated CD56 þ /CD3À NK cells at day þ 2 after transplant. Three had predicted NK alloreactivity in GvHD direction, two in rejection direction. Late graft failure occurred in one with NK alloreactivity in rejection direction. This patient was later successfully grafted with another donor with NK alloreactivity in GvHD direction. One patient relapsed in spite of predicted NK alloreactivity. Analysis of tumor escape mechanisms revealed that the patient's leukemia cells were resistant to perforin-mediated lysis. Four patients developed grade II acute GvHD post transplant, it is impossible to ascertain whether this is due to the graft or NK cells as NK cells were given with the transplant. Two of the six patients remain alive and well. Three died due to infectious complications, one due to relapse. 45 Slavin et al used IL-2-activated NK cells (CD 56 þ selected) following transplantation from haploidentical 3 sibling, 4 or unrelated 1 donors. Patients with hematological malignancies (including acute leukemia and lymphoid malignancies), age 4-63 (median 25) years had relapsed or were at very high risk. Donor lymphocytes were incubated for 4 days with IL-2 and then positively selected for CD56 þ . Purity of CD56 þ was 39 (30-71)%, CD3 þ was 3 (2-21)%. The number of CD56 þ cells was 120 (10-600) Â 10 6 cells. Cell infusion was uneventful. No GvHD was observed. One patient with relapsed ALL and a patient with MDS transplanted from a KIR nonalloreactive mother achieved CR. Four patients are alive; one with disease; three with no evidence of disease at 9-22 months post-HSCT. 48 Koehl et al reported on three pediatric patients with multiply relapsed ALL 2 and AML 1 treated with repeated transfusions of IL-2-activated NK cells post haploidentical HSCT from parental donors (single dose: 3-34 Â 10 6 CD56 þ /CD3À/kg). Blast persistence (37-97%) was demonstrated in pretransplant bone marrow in all three patients. KIR mismatches in GvHD direction were demonstrated in all donor:recipient pairs. All patients reached complete remission 4 weeks post-HSCT, which was accompanied by complete donor chimerism. NK-cell infusion was well tolerated, two patients died of transplant-related complications, one patient died of relapse. 43 Data available so far show that ex vivo purification of donor NK cells from leukapheresis products is technically feasible, and large numbers of CD56-positive, highly CD3-depleted cells can be obtained using the CliniMACS s twostep procedure of T-cell depletion and NK-cell enrichment. NK cells are infused without immediate adverse events and without inducing GvHD. Clinical data on efficacy are very limited at this point in time. Whether NK-DLI will revert impending graft rejection and promote graft versus leukemia effect requires additional studies. One could argue that NK-DLI will not add any benefit to NK cells recovering in the patient post transplant. In addition, it will be difficult to separate NK-cell effects from effects of small number of residual T cells in the product.
Future prospects
Future studies will determine the usefulness, if any, of NK cells as adoptive immunotherapy in recipients of HSCT from haploidentical and other donors (see Table 4 ). Open issues include NK-cell doses, timing, and appropriate selection of donor and recipients. The use of NK cells as adoptive immunotherapy will help to better define the clinical impact of NK-cell alloreactivity including the importance of KIR mismatching. Whether these cells should be used preemptively or as a salvage treatment is unknown. Timing may be crucial, more for scientific evaluation than for patient care. Effects of NK cells given simultaneously with the transplants will be much harder to measure than NK cells given later in the course. Some groups have used NK cells purified from the stem cell product and the impact of mobilization on NK cells needs to be studied. Other groups have reported on enrichment of NK cells by depletion of T and B cells. So far the safety record of these cells is of interest as they do not appear to induce any measurable GvHD. Appropriate targets need to be defined, it is far from clear whether NK cells would be more effective in patients with AML than in other disease entities. Some encouraging data comes from work with solid tumors. 49 Whether NK cells will be used without additional manipulation, or whether stimulation and culture either short or medium term with cytokines such as IL-2 will prove to be more effective awaits further studies. 50 Purging and enrichment technology using magnetic beads for clinical application is technologically fascinating but expensive, in direct costs of antibodies and columns and the time of laboratory personnel. The NK-cell enrichment technology will require some improvement for broad application. Some donors have low circulating NK-cell counts and one wonders whether it would be an option to mobilize NK cells, possibly with physical activity/adrenaline. 51 We are currently running a phase II study expanding on the pilot data and we will learn more about safety and feasibility but not about efficacy.
The burden of proof of principle and of usefulness in clinical practice lies therefore with those who want to apply this technology. A multiinstitutional phase III trial in recipients of haploidentical HSCT comparing standard transplant to transplant plus NK-DLI could be instrumental in establishing the clinical role, if any, of adoptive NK-cell therapy. Table 4 Issues in harvesting, purification and administration of NK cells Information on safety and on NK-cell effects to be expected
Production issues Comment
Patient selection issues
AML vs other diseases NK alloreactivity has been shown to be strongest in myeloid leukemia and possibly absent in other diseases, but this has not been studied prospectively and not using adoptive immunotherapy protocols
Donor selection issues
Any suitable haploidentical donor vs donor with known NK-alloreactivity
The skeptical approach of not restricting inclusion for adoptive immunotherapy protocols to donors with known NK-alloreactivity will allow for testing of NK-cell effects in donor recipient pairs with or without predicted or measured NK-cell alloreactivity Other allogeneic donors or autologous NK cells There is little or no information available
